




# *R&D pipeline Update*

*First half in Fiscal 2007*

**Kiyoshi Kitazawa**

Managing Director, General Manager  
Strategic Product Planning Dept.

November 6, 2007



Takeda Pharmaceutical Company Limited

## **Core therapeutic areas**

**Franchise I: Lifestyle-related diseases**

**Franchise II: Oncology and urological diseases**

**Franchise III: CNS (including bone/joint diseases)**

**Franchise IV: Gastroenterological diseases**

## Franchise I: Lifestyle-related diseases (1)

Development code	Indications (region)	Ph II	Ph III	NDA	Approval
AD-4833	Combination drug with sustained-release metformin (US)				
	Concomitant therapy with metformin (Japan)				
	Concomitant therapy with insulin (Japan)				
	Delay in progression of Atherosclerosis (US)				
AO-128	Impaired glucose tolerance (IGT) (Japan)				
SYR-322	Diabetes (US, Europe)				
	Diabetes (Japan)				
SYR-472	Diabetes (US, Europe)				
TAK-583	Painful diabetic neuropathy (US, Europe, Japan)				
	Diabetic peripheral neuropathy (US, Europe, Japan)				
	Postherpetic neuralgia (US, Europe)				
TAK-428	Diabetic neuropathy (US, Europe)				
KAD-1229	Concomitant therapy with alpha-glucosidase inhibitor (Japan)				
	Concomitant therapy with insulin resistance-improving agent (Japan)				

Stage progress before FY07 1Q(07, July)results <sup>3</sup>

Takeda Pharmaceutical Company Limited

## Franchise I: Lifestyle-related diseases (2)

Development code	Indications (region)	Ph II	Ph III	NDA	Approval
TCV-116	Fixed-combination drug with diuretic (Japan, Europe)				
	High dose (Japan)				
	Diabetic retinopathy (Europe) DIRECT Study				
TAK-491	Hypertension (US, Europe)				
TAK-536	Hypertension (US, Europe)				
	Hypertension (Japan)				
TAK-475	Hypercholesterolemia (US, Europe)				
	Hypercholesterolemia (Japan)				
TAK-442	Venous/Arterial Thromboembolism (US, Europe)				
ATL-962	Obesity (Japan)				

Stage progress before FY07 1Q(07, July)results

Stage progress after FY07 1Q (07, July) results

<sup>4</sup>

Takeda Pharmaceutical Company Limited

## Franchise II: Oncology and urological diseases

Development code	Indications (region)	Ph II	Ph III	NDA	Approval
TAP-144SR (6M)	Prostate cancer (Europe)				
AF37702 (Hematide)	Chronic kidney disease (CKD) related anemia (US, Europe)				
	Chronic kidney disease (CKD) related anemia (Japan)				
TAK-851	HPV infection (US, Europe)				
EMD72000	Gastric cancer, Non-small cell lung cancer, Colorectal cancer (US, Europe, Japan)				

Stage progress after FY07 1Q (07, July) results

5

Takeda Pharmaceutical Company Limited

## Franchise III: Central nervous system diseases (including bone/joint diseases)

Development code	Indications (region)	Ph II	Ph III	NDA	Approval
TAK-375	Insomnia (Europe)				
	Insomnia (Japan)				
	Alzheimer's sleep / wake disturbance (US)				
	Circadian rhythm sleep disorder (US)				
TAK-783	Rheumatoid arthritis (US, Europe)				
Lu AA21004	Mood and anxiety disorders (Europe)				
Lu AA24530	Mood and anxiety disorders (Europe)				
NE-58095	Once-a-week formulation (Japan)				
	Paget's disease of bone (Japan)				

Stage progress before FY07 1Q(07, July)results

Stage progress after FY07 1Q (07, July) results

6

Takeda Pharmaceutical Company Limited

## Franchise IV: Gastroenterological and other diseases

Development code	Indications (region)	Ph II	Ph III	NDA	Approval
AG-1749	Secondary eradication of <i>H. pylori</i> (Japan)				
	Risk reduction of NSAID-associated gastric ulcer (Japan)				
SPI-0211	Irritable bowel syndrome with constipation (US)				
	Opioid-induced bowel dysfunction (US)				
SNT-MC17	Friedreich's ataxia (Europe)				
	Duchenne muscular dystrophy (Europe)				
TAK-390MR	Erosive esophagitis and non-erosive gastro-esophageal reflux disease (US)				
TAK-242	Severe sepsis (US, Europe, Japan)				

Stage progress before FY07 1Q(07, July) results

Stage progress after FY07 1Q (07, July) results

7

Takeda Pharmaceutical Company Limited

## TAK-783

- ◆ **T-cell function regulator**  
(orally taken treatment for Rheumatoid arthritis)
- ◆ **Discovered and created by Takeda**

### <Profile>

Based on non-clinical data, this drug is expected to correct autoimmune reaction by Th1 lymph cell, that is supposed to be a cause of RA.

As this drug acts on the cause of RA and may have wider safety allowance than immune depression agents, it is expected to have potential to become a first-line therapy for RA.

8

Takeda Pharmaceutical Company Limited

# Lu AA21004, Lu AA24530

- ◆ **Licenser: Lundbeck (Denmark)**
- ◆ **Indications (planned): mood and anxiety disorders**
- ◆ **Development Stage**

Lu AA21004 --- phase II study results under analysis

Lu AA24530 --- phase II study started (October, 2007)

## <Profile>

Preclinical models have demonstrated that the compounds have the potential to address

important unmet needs for patients in terms of both fast onset of effect and increased efficacy.

### <Phase II study of Lu AA21004>

Multicenter, double-blind, placebo-controlled trial including 426 patients with major depression (4 arms: Lu AA21004 (5mg, 10mg), placebo, active comparator

### <Phase II study of Lu AA24530>

600 patients with depression, treatment period: 6 weeks

9

Takeda Pharmaceutical Company Limited

## Forward-Looking Statements

*This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at this time.*

*Certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this presentation. These risks and uncertainties include, but are not limited to, the economic circumstances surrounding the Company's business; competitive pressure; relative laws and regulations; product development programs; and changes in exchange rates.*

*We assume no obligation to update or reverse any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.*